These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 21536664

  • 1. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
    Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J.
    Ann Oncol; 2012 Feb; 23(2):395-401. PubMed ID: 21536664
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B.
    J Clin Oncol; 2008 Jan 01; 26(1):127-31. PubMed ID: 18165647
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sequential sorafenib and sunitinib for renal cell carcinoma.
    Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B.
    J Urol; 2009 Jul 01; 182(1):29-34; discussion 34. PubMed ID: 19447417
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
    Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C.
    Cancer; 2009 Jan 01; 115(1):61-7. PubMed ID: 19051290
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
    Lee JL, Park I, Park K, Park S, Ahn Y, Ahn JH, Kim TW, Ahn S, Song C, Hong JH, Kim CS, Ahn H.
    J Cancer Res Clin Oncol; 2012 Apr 01; 138(4):687-93. PubMed ID: 22237457
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
    Buchler T, Pavlik T, Bortlicek Z, Poprach A, Vyzula R, Abrahamova J, Melichar B.
    Med Oncol; 2012 Dec 01; 29(5):3321-4. PubMed ID: 22752573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.